Somnus Therapeutics, Inc.
Insomnia Therapeutics
Somnus Therapeautics Insomnia
Somnus Therapeautics Insomnia Somnus Therapeutics Somnus Therapeautics Insomnia Somnus Therapeutics Insomnia Product Somnus Therapeautics Insomnia Insomnia Information from Somnus Therapeutics Somnus Therapeautics Insomnia Somnus Therapeutics News and Events Somnus Therapeautics Insomnia Contact the Insomnia Specialists Somnus Therapeutics Somnus Therapeautics Insomnia
Somnus Therapeautics Insomnia
  overview
Somnus Therapeutics Insomnia
  about
Somnus Therapeutics Insomnia
  sleep & insomnia
Somnus Therapeutics Insomnia
  press releases
Somnus Therapeutics Insomnia
  information
Somnus Therapeutics Insomnia
  management
 
  publications
  directions
  board of directors
  research presentations
  scientific advisors
         

Chief Regulatory Officer – Christine Blumhardt, PharmD

20 years experience in pharmaceutical industry

  • VP Regulatory Affairs/QA, Peptimmune, Inc. (also business development and board of directors)
  • VP Global Regulatory Affairs for pharmaceutical, biological, vaccine and devices across all therapeutic areas, Wyeth (NYSE: WYE)
  • Regulatory Affairs and Clinical Research positions GlaxoSmithKline, SmithKline Beecham, Beecham Laboratories
  • Post-doctoral fellowship NIH, including FDA Interagency Agreement Officer, Neuropharm Division and special agent for US Senate Committee on Labor and Human Resources to review psychiatric drug labeling.
  • Assistant Professor, Clinical Pharmacy, Massachusetts College of Pharmacy
  • BS Chemistry/Biology Penn State University, BS Pharmacy Temple University, PharmD (psychopharm) University of Tennessee.



 
 
Somnus Therapeautics Insomnia
Somnus Therapeautics Insomnia